Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4
ALLO posts a narrower Q4 loss than expected, cuts expenses and advances key CAR-T studies, with cash projected to fund operations into 2028.
Open original sourceLoading market dashboard
ALLO posts a narrower Q4 loss than expected, cuts expenses and advances key CAR-T studies, with cash projected to fund operations into 2028.
Open original source